Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00003792 · Baylor Health Care System, Other · Completed
Key facts
| NCT number | NCT00003792 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial |
| Lead sponsor | Baylor Health Care System, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Procedure |
| Interventions | MART-1 antigen, filgrastim, flu matrix peptide p58-66, gp100 antigen, recombinant MAGE-3.1 antigen, tyrosinase peptide, in vitro-treated peripheral blood stem cell transplantation |
| Start date | Apr 1, 1999 |
| Completion | Oct 1, 2006 |
| First posted | Jul 16, 2004 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: